DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases

Santoro SW, Joyce GF: A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 1997, 94:4262-4266. Liu H, Yu X, Chen Y, Zhang J, Wu B, Zheng L, Haruehanroengra P, Wang R, Li S, Lin J, et al: Crystal structure of an RNA-cleaving DNAzyme. Nat Commun 2017, 8:2006. Zhang N, Ashizawa T: RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev 2017, 44:17-29. Chatterjee A, Saha S, Chakraborty A, Silva-Fernandes A, Mandal SM, Neves-Carvalho A, Liu Y, Pandita RK, Hegde ML, Hegde PM, et al: The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis. PLoS Genet 2015, 11:e1004749. Enokido Y, Tamura T, Ito H, Arumughan A, Komuro A, Shiwaku H, Sone M, Foulle R, Sawada H, Ishiguro H, et al: Mutant huntingtin impairs Ku70-mediated DNA repair. J Cell Biol 2010, 189:425-443. Fujita K, Nakamura Y, Oka T, Ito H, Tamura T, Tagawa K, Sasabe T, Katsuta A, Motoki K, Shiwaku H, et al: A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases. Nat Commun 2013, 4:1816. Gao R, Liu Y, Silva-Fernandes A, Fang X, Paulucci-Holthauzen A, Chatterjee A, Zhang HL, Matsuura T, Choudhary S, Ashizawa T, et al: Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3. PLoS Genet 2015, 11:e1004834. Illuzzi J, Yerkes S, Parekh-Olmedo H, Kmiec EB: DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J Neurosci Res 2009, 87:733-747. Qi ML, Tagawa K, Enokido Y, Yoshimura N, Wada Y, Watase K, Ishiura S, Kanazawa I, Botas J, Saitoe M, et al: Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 2007, 9:402-414. Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC: Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature 2017, 545:108-111. Bence NF, Sampat RM, Kopito RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI: Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311:1471-1474. Kuiper EF, de Mattos EP, Jardim LB, Kampinga HH, Bergink S: Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch. Front Neurosci 2017, 11:145. 14.Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, Clark TW, Bouzou B, Cha JH: Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008, 28:10720-10733. Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, et al: Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol Dis 2006, 22:233-241. Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, Wheeler VC, Bang AG, Cleveland DW, Lagier-Tourenne C: Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron 2017, 94:48–57 e44. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, Orr HT: Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53. Burke KA, Kauffman KJ, Umbaugh CS, Frey SL, Legleiter J: The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin. J Biol Chem 2013, 288:14993-15005. Gao X, Campbell WAt, Chaibva M, Jain P, Leslie AE, Frey SL, Legleiter J: Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes. Biochemistry 2016, 55:92-102. Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer JC, et al: Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron 2017, 94:93–107 e106. Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, Malorni W, Davies KJ, Carafoli E, Scorrano L: Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med 2010, 2:490-503. Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ: N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 2008, 28:2783-2792. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002, 5:731-736. Banez-Coronel M, Ayhan F, Tarabochia AD, Zu T, Perez BA, Tusi SK, Pletnikova O, Borchelt DR, Ross CA, Margolis RL, et al: RAN Translation in Huntington Disease. Neuron 2015, 88:667-677. Cleary JD, Pattamatta A, Ranum LPW: Repeat-associated non-ATG (RAN) translation. J Biol Chem 2018, 293:16127-16141. Cleary JD, Ranum LP: New developments in RAN translation: insights from multiple diseases. Curr Opin Genet Dev 2017, 44:125-134. Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M: Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases. Front Neurosci 2018, 12:75. Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL: CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease. Int J Mol Sci 2017, 18. Marthaler AG, Tubsuwan A, Schmid B, Poulsen UB, Engelbrecht AF, Mau-Holzmann UA, Hyttel P, Nielsen TT, Nielsen JE, Holst B: Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H266. Stem Cell Res 2016, 16:202-205. McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, Zhao H, Kordasiewicz HB, Shakkottai VG, Paulson HL: Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol 2018, 84:64-77. Merienne N, Vachey G, de Longprez L, Meunier C, Zimmer V, Perriard G, Canales M, Mathias A, Herrgott L, Beltraminelli T, et al: The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. Cell Rep 2017, 20:2980-2991. Monteys AM, Ebanks SA, Keiser MS, Davidson BL: CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo. Molecular Therapy 2017, 25:12-23. Moore LR, Keller L, Bushart DD, Delatorre RG, Li D, McLoughlin HS, do Carmo Costa M, Shakkottai VG, Smith GD, Paulson HL: Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line. Stem Cell Res 2019, 39:101504. Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, Hung G, Kordasiewicz HB, Paulson HL, McLoughlin HS: Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Mol Ther Nucleic Acids 2017, 7:200-210. Ouyang S, Xie Y, Xiong Z, Yang Y, Xian Y, Ou Z, Song B, Chen Y, Xie Y, Li H, Sun X: CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells. Stem Cells Dev 2018, 27:756-770. Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM: Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 2017, 544:362-366. Tabrizi SJ, Smith AV, Bennett CF: Targeting Huntingtin in Patients with Huntington's Disease. Reply. N Engl J Med 2019, 381:1181-1182. Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, Sun X, Qin Z, Jin P, Li S, Li XJ: CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease. J Clin Invest 2017, 127:2719-2724. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR: Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019. Komor AC, Badran AH, Liu DR: CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell 2017, 169:559. Liu C, Zhang L, Liu H, Cheng K: Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 2017, 266:17-26. Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 2017, 8:14454. Friedrich J, Kordasiewicz HB, O'Callaghan B, Handler HP, Wagener C, Duvick L, Swayze EE, Rainwater O, Hofstra B, Benneyworth M, et al: Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight 2018, 3. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, et al: Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044. Niu C, Prakash TP, Kim A, Quach JL, Huryn LA, Yang Y, Lopez E, Jazayeri A, Hung G, Sopher BL, et al: Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Sci Transl Med 2018, 10. Datson NA, Gonzalez-Barriga A, Kourkouta E, Weij R, van de Giessen J, Mulders S, Kontkanen O, Heikkinen T, Lehtimaki K, van Deutekom JC: The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One 2017, 12:e0171127. Gagnon KT, Watts JK, Pendergraff HM, Montaillier C, Thai D, Potier P, Corey DR: Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. J Am Chem Soc 2011, 133:8404-8407. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR: Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009, 27:478-484. Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME: Transcription Factor-Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol 2018, 79:e51. Xia G, Santostefano K, Hamazaki T, Liu J, Subramony SH, Terada N, Ashizawa T: Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J Mol Neurosci 2013, 51:237-248. Brown AK, Li J, Pavot CMB, Lu Y: A lead-dependent DNAzyme with a two-step mechanism. Biochemistry 2003, 42:7152-7161. Romani AM: Cellular magnesium homeostasis. Arch Biochem Biophys 2011, 512:1-23. Ryschon TW, Rosenstein DL, Rubinow DR, Niemela JE, Elin RJ, Balaban RS: Relationship between skeletal muscle intracellular ionized magnesium and measurements of blood magnesium. J Lab Clin Med 1996, 127:207-213. Wolf FI, Trapani V: Cell (patho)physiology of magnesium. Clin Sci (Lond) 2008, 114:27-35. Iotti S, Frassineti C, Alderighi L, Sabatini A, Vacca A, Barbiroli B: In vivo assessment of free magnesium concentration in human brain by 31P MRS. A new calibration curve based on a mathematical algorithm. NMR Biomed 1996, 9:24–32. Korolev N, Lyubartsev AP, Rupprecht A, Nordenskiold L: Competitive binding of Mg2+, Ca2+, Na+, and K+ ions to DNA in oriented DNA fibers: experimental and Monte Carlo simulation results. Biophys J 1999, 77:2736-2749. Bagur R, Hajnoczky G: Intracellular Ca(2+) Sensing: Its Role in Calcium Homeostasis and Signaling. Mol Cell 2017, 66:780-788. Zhou W, Vazin M, Yu T, Ding J, Liu J: In Vitro Selection of Chromium-Dependent DNAzymes for Sensing Chromium(III) and Chromium(VI). Chemistry 2016, 22:9835-9840. Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ: Targeting noncoding RNAs in disease. J Clin Invest 2017, 127:761-771. Hegarty JP, Stewart DB, Sr.: Advances in therapeutic bacterial antisense biotechnology. Appl Microbiol Biotechnol 2018, 102:1055-1065. Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS: Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules 2017, 22. Wurster CD, Ludolph AC: Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 2018, 11:1756286418776932. Kim HK, Liu J, Li J, Nagraj N, Li M, Pavot CM, Lu Y: Metal-dependent global folding and activity of the 8-17 DNAzyme studied by fluorescence resonance energy transfer. J Am Chem Soc 2007, 129:6896-6902. Finkbeiner S: Huntington's Disease. Cold Spring Harb Perspect Biol 2011, 3. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, et al: Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 2010, 285:8808-8823. Estrada-Sanchez AM, Rebec GV: Role of cerebral cortex in the neuropathology of Huntington's disease. Front Neural Circuits 2013, 7:19. Krencik R, Seo K, van Asperen JV, Basu N, Cvetkovic C, Barlas S, Chen R, Ludwig C, Wang C, Ward ME, et al: Systematic Three-Dimensional Coculture Rapidly Recapitulates Interactions between Human Neurons and Astrocytes. Stem Cell Reports 2017, 9:1745-1753. Cvetkovic C, Basu N, Krencik R: Synaptic Microcircuit Modeling with 3D Cocultures of Astrocytes and Neurons from Human Pluripotent Stem Cells. J Vis Exp 2018. Costa MD, Paulson HL: Toward understanding Machado-Joseph disease. Prog Neurobiol 2012, 97:239-257. Burnett BG, Pittman RN: The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A 2005, 102:4330-4335. Feng Q, Miao Y, Ge J, Yuan Y, Zuo Y, Qian L, Liu J, Cheng Q, Guo T, Zhang L, et al: ATXN3 Positively Regulates Type I IFN Antiviral Response by Deubiquitinating and Stabilizing HDAC3. J Immunol 2018, 201:675-687. Gao R, Chakraborty A, Geater C, Pradhan S, Gordon KL, Snowden J, Yuan S, Dickey AS, Choudhary S, Ashizawa T, et al: Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription. Elife 2019, 8. Herzog LK, Kevei E, Marchante R, Bottcher C, Bindesboll C, Lystad AH, Pfeiffer A, Gierisch ME, Salomons FA, Simonsen A, et al: The Machado-Joseph disease deubiquitylase ataxin-3 interacts with LC3C/GABARAP and promotes autophagy. Aging Cell 2020, 19:e13051. Zhou L, Wang H, Chen D, Gao F, Ying Z, Wang G: p62/sequestosome 1 regulates aggresome formation of pathogenic ataxin-3 with expanded polyglutamine. Int J Mol Sci 2014, 15:14997-15010. Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, Wuellner U: Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 2007, 362:734-739. Switonski PM, Fiszer A, Kazmierska K, Kurpisz M, Krzyzosiak WJ, Figiel M: Mouse ataxin-3 functional knock-out model. Neuromolecular Med 2011, 13:54-65. Mori F, Tanji K, Odagiri S, Toyoshima Y, Yoshida M, Kakita A, Takahashi H, Wakabayashi K: Autophagy-related proteins (p62, NBR1 and LC3) in intranuclear inclusions in neurodegenerative diseases. Neurosci Lett 2012, 522:134-138. Seidel K, den Dunnen WF, Schultz C, Paulson H, Frank S, de Vos RA, Brunt ER, Deller T, Kampinga HH, Rub U: Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 2010, 120:449-460. Zeng L, Wang B, Merillat SA, Minakawa EN, Perkins MD, Ramani B, Tallaksen-Greene SJ, Costa MDC, Albin RL, Paulson HL: Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3. Neurobiol Dis 2015, 82:281-288. Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, Lee SS, Wilkinson A, Yang GS, Yuen MM, et al: CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 2007, 8:126. Durcan TM, Kontogiannea M, Thorarinsdottir T, Fallon L, Williams AJ, Djarmati A, Fantaneanu T, Paulson HL, Fon EA: The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum Mol Genet 2011, 20:141-154. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W: PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biology 2010, 12:119-U170. Sauve V, Sung G, Soya N, Kozlov G, Blaimschein N, Miotto LS, Trempe JF, Lukacs GL, Gehring K: Mechanism of parkin activation by phosphorylation (vol 25, pg 623, 2018). Nature Structural & Molecular Biology 2018, 25:744-744. Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, Manoharan M, Kirchhausen T, Lieberman J: Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol 2015, 33:870-876. Tian T, Li J, Xie C, Sun Y, Lei H, Liu X, Xia J, Shi J, Wang L, Lu W, Fan C: Targeted Imaging of Brain Tumors with a Framework Nucleic Acid Probe. ACS Appl Mater Interfaces 2018, 10:3414-3420. Walsh AS, Yin H, Erben CM, Wood MJ, Turberfield AJ: DNA cage delivery to mammalian cells. ACS Nano 2011, 5:5427-5432. Yang J, Jiang Q, He L, Zhan P, Liu Q, Liu S, Fu M, Liu J, Li C, Ding B: Self-Assembled Double-Bundle DNA Tetrahedron for Efficient Antisense Delivery. ACS Appl Mater Interfaces 2018, 10:23693-23699. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ: Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2020, 15:313-320. Gait MJ, Arzumanov AA, McClorey G, Godfrey C, Betts C, Hammond S, Wood MJA: Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment. Nucleic Acid Ther 2019, 29:1-12. Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, Meijboom KE, Zhou H, Muntoni F, Talbot K, et al: Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A 2016, 113:10962-10967. Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP, 3rd, Hou S, Esposito AA, Ketova T, Welsher K, et al: Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun 2020, 11:983. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, King RH, Pook MA, Huxley C, Chamberlain S: YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002, 11:1075-1094. Gould VFC: Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease). Neurotherapeutics 2012, 9:285-296. Hyjek M, Figiel M, Nowotny M: RNases H: Structure and mechanism. DNA Repair (Amst) 2019, 84:102672. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z: A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 2005, 33:1671-1677. Wang Y, Juranek S, Li H, Sheng G, Tuschl T, Patel DJ: Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 2008, 456:921-926. Jafar-Nejad P, Ward CS, Richman R, Orr HT, Zoghbi HY: Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci U S A 2011, 108:2142-2147. Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T, Lu HC, Lagalwar S, Duvick L, Kang H, et al: RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 2013, 498:325-331. Kozlowski P, de Mezer M, Krzyzosiak WJ: Trinucleotide repeats in human genome and exome. Nucleic Acids Res 2010, 38:4027-4039. Matilla A, Roberson ED, Banfi S, Morales J, Armstrong DL, Burright EN, Orr HT, Sweatt JD, Zoghbi HY, Matzuk MM: Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J Neurosci 1998, 18:5508-5516. Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al: Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 2017, 544:367-371. Huynh DP, Maalouf M, Silva AJ, Schweizer FE, Pulst SM: Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PLoS One 2009, 4:e6235. Rue L, Banez-Coronel M, Creus-Muncunill J, Giralt A, Alcala-Vida R, Mentxaka G, Kagerbauer B, Zomeno-Abellan MT, Aranda Z, Venturi V, et al: Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest 2016, 126:4319-4330. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, et al: Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015, 372:1987-1995. Cairns MJ, King A, Sun LQ: Optimisation of the 10-23 DNAzyme-substrate pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites. Nucleic Acids Res 2003, 31:2883-2889. Kurkiewicz A, Cooper A, McIlwaine E, Cumming SA, Adam B, Krahe R, Puymirat J, Schoser B, Timchenko L, Ashizawa T, et al: Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial. PLoS One 2020, 15:e0231000. Hu J, Rong Z, Gong X, Zhou Z, Sharma VK, Xing C, Watts JK, Corey DR, Mootha VV: Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in Fuchs' dystrophy. Hum Mol Genet 2018, 27:1015-1026. Benhamou RI, Angelbello AJ, Wang ET, Disney MD: A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways. Cell Chem Biol 2020, 27:223–231 e224. Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D, et al: Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 2016, 90:535-550. Drozd M, Delhaye S, Maurin T, Castagnola S, Grossi M, Brau F, Jarjat M, Willemsen R, Capovilla M, Hukema RK, et al: Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS. Mol Ther Nucleic Acids 2019, 18:546-553. Ishiura H, Shibata S, Yoshimura J, Suzuki Y, Qu W, Doi K, Almansour MA, Kikuchi JK, Taira M, Mitsui J, et al: Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat Genet 2019, 51:1222–1232. White MC, Gao R, Xu W, Mandal SM, Lim JG, Hazra TK, Wakamiya M, Edwards SF, Raskin S, Teive HA, et al: Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genet 2010, 6:e1000984. Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A, Tokuda E, Zamiri B, Gall-Duncan T, Mirceta M, et al: Regulatory Role of RNA Chaperone TDP-43 for RNA Misfolding and Repeat-Associated Translation in SCA31. Neuron 2017, 94:108–124 e107. Seixas AI, Loureiro JR, Costa C, Ordonez-Ugalde A, Marcelino H, Oliveira CL, Loureiro JL, Dhingra A, Brandao E, Cruz VT, et al: A Pentanucleotide ATTTC Repeat Insertion in the Non-coding Region of DAB1, Mapping to SCA37, Causes Spinocerebellar Ataxia. Am J Hum Genet 2017, 101:87-103. Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, Yu XX, Cortes CJ, Bennett CF, Monia BP, et al: Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 2014, 7:774-784. Sahashi K, Katsuno M, Hung G, Adachi H, Kondo N, Nakatsuji H, Tohnai G, Iida M, Bennett CF, Sobue G: Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2015, 24:5985-5994. Kaemmerer WF, Grondin RC: The effects of huntingtin-lowering: what do we know so far? Degener Neurol Neuro 2019, 9:3-17. Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, Di Maria E, Donato SD, Kaemmerer WF: A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009, 217:312-319. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel JP, Zamore PD, Aronin N: Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009, 19:774-778. Pulst SM: Degenerative ataxias, from genes to therapies: The 2015 Cotzias Lecture. Neurology 2016, 86:2284-2290. Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC: Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Mol Ther Nucleic Acids 2017, 8:232-242.